Stoke Therapeutics, INC Form 4 insider transactions

Stoke Therapeutics' General Counsel, Jonathan Allan, acquired 6,000 common shares and received a new grant of 12,000 performance stock units.

Stoke Therapeutics Director Edward M. Kaye received a new grant of 52,500 performance stock units and acquired 26,250 common shares through vesting.

Stoke Therapeutics General Counsel Jonathan Allan sold 13,712 shares of common stock at $15 per share under a pre-arranged Rule 10b5-1 trading plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, disclosed a pre-planned sale of 4,504 common shares set for August 1, 2025, under a Rule 10b5-1 trading plan.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 4,503 shares of common stock for approximately $52,370 through a pre-established Rule 10b5-1 trading plan.

Stoke Therapeutics, Inc. Director Arthur A. Levin acquired 1,210 shares of common stock through the conversion of Restricted Stock Units as part of a pre-arranged trading plan.

Skorpios Trust, a 10% owner and director of Stoke Therapeutics, Inc. (STOK), has reported the sale of 3,000,000 shares of common stock at $10.20 per share.

Stoke Therapeutics, Inc. Director Julie Smith was granted 29,747 stock options with a strike price of $10.90, aligning her interests with shareholders.

Stoke Therapeutics, Inc. Director Arthur A. Levin was granted 29,747 stock options with an exercise price of $10.90, aligning his interests with long-term shareholder value.

Stoke Therapeutics, Inc. Director Garry E. Menzel was granted 29,747 stock options with an exercise price of $10.9 per share, aligning his interests with shareholder value.

Stoke Therapeutics, Inc. Director Adrian R. Krainer was granted 29,747 stock options with an exercise price of $10.9 per share, aligning his interests with shareholder value.

Stoke Therapeutics, Inc. Director Seth Loring Harrison has been granted 29,747 stock options with an exercise price of $10.90, aligning his interests with shareholder value.

Stoke Therapeutics, Inc. Director Jennifer Burstein was granted 29,747 stock options with an exercise price of $10.90, vesting by June 2026.

Stoke Therapeutics' Chief Medical Officer, Barry Ticho, sold 8,216 shares of common stock in early June 2025, pursuant to a Rule 10b5-1 trading plan established in December 2024.

Chief Medical Officer of Stoke Therapeutics, Barry Ticho, sold shares of common stock on May 1st and 2nd, 2025, under a pre-arranged 10b5-1 trading plan.

Director Arthur A. Levin reports exercising stock options and changes in beneficial ownership of Stoke Therapeutics, Inc. shares.

Ian F. Smith, Interim CEO of Stoke Therapeutics, acquired stock options for 238,420 shares of common stock on March 20, 2025.

Arthur Tzianabos, Interim Executive Chair of Stoke Therapeutics, acquires stock options.

Chief Financial Officer Thomas Leggett of Stoke Therapeutics acquired stock options and restricted stock units on March 20, 2025, according to a Form 4 filing with the SEC.

Director Arthur A. Levin acquired 4,842 Restricted Stock Units in Stoke Therapeutics, Inc. on March 19, 2025, vesting quarterly until December 31, 2025.

Director Kaye Edward M. MD reports sales of Stoke Therapeutics common stock to cover tax obligations and receives stock options and restricted stock units.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, sold shares to cover tax liabilities while also acquiring stock options and restricted stock units.

Jonathan Allan, General Counsel & Corporate Secretary of Stoke Therapeutics, reports sales of common stock to cover tax obligations and the grant of stock options and restricted stock units.

Jonathan Allan, General Counsel & Corp Sec of Stoke Therapeutics, reports acquisition of shares through stock options and employee stock purchase plan.

Barry Ticho, Chief Medical Officer of Stoke Therapeutics, reports the acquisition of common stock through the vesting of restricted stock units.

CEO Edward M. Kaye of Stoke Therapeutics exercised stock options and sold shares on March 15, 2025, according to a Form 4 filing with the SEC.

CEO of Stoke Therapeutics, Edward M. Kaye, reports exercising stock options and changes in beneficial ownership of company stock.

Skorpios Trust, a significant shareholder of Stoke Therapeutics, sold 2 million shares of common stock at $11.50 per share.

A Stoke Therapeutics executive sold shares to cover tax liabilities related to vesting restricted stock units.

Stoke Therapeutics' General Counsel, Jonathan Allan, sold a total of 13,666 shares of common stock in multiple transactions on December 9, 2024, under a pre-arranged 10b5-1 trading plan and to cover tax liabilities.